The Key Players in Global Hyperphosphatemia Drugs Market 2015-2019

Friday 14 August 2015, Amsterdam

The report recognizes the following companies as the key players in the Global Hyperphosphatemia Drugs Market: Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire and Vifor Pharma

The other prominent vendors are: Alkem, Amgen, Ardelyx, AstraZeneca, Baxter, Bayer, Chugai Pharmaceutical, Japan Tobacco, Kissei Pharmaceutical, Kyowa Hakko Kirin, Mylan, Natco, Novartis, Opko Health, Panion & BF Biotech, Roxane Laboratories, Sandoz, Synthon and Torri Pharmaceutical

Commenting on the report, an analyst said: “The market presents huge growth opportunities for vendors because of the growing incidence of hyperphosphatemia and associated high pill burden. Currently, many companies are investing in the discovery and R&D of drugs for the condition. For instance, Tenapor by Ardelyx and AstraZeneca is in phase II developmental stage. The entry of this drug will likely reduce the pill burden associated with the condition. Similarly, RDX002, a type 2a sodium phosphate cotransporter (NaP2b) inhibitor, is being developed by Sanofi. Ardelyx licensed the drug to Sanofi, but retained its co-promotion rights in the US. The launch of novel drug candidates with higher efficacy and safety profile, currently under different stages of development, will contribute to market growth.”

According to the report, diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The USRDS reported in 2014 that 13.6% adults in the US had CKD, of which diabetes accounted for 44% of kidney failure cases. It also reported in 2012 that high blood pressure led to an increase of 7.7% of kidney failure cases from 2000 to 2010. The International Diabetes Federation reported in 2014 that 387 million people had diabetes in the same year, which is expected to increase by 2035. WHO reported in 2013 that currently over 1 billion people have high blood pressure and about 9.4 million people die from the condition annually worldwide.

Further, the report states that non-adherence to treatment regimens is a major challenge faced by the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Global Hyperphosphatemia Drugs Market 2015-2019

Global Hyperphosphatemia Drugs Market 2015-2019

Publish date : August 2015
Report code : ASDR-213649
Pages : 89

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News